Pfizer and Merck are among the drugmakers with enough cash on hand to invest $10 billion or more in mergers and acquisitions this year. However, expiring patents on blockbuster drugs, more muscular biotechnology companies and stronger competition might impede Big Pharma's ability to conclude large deals, an Ernst & Young analysis found.
Big Pharma deals may lie ahead in 2013
SmartBrief Job Listings for Health Care
|President/Chief Executive Officer||
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Director, Payer Marketing||
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
|Chief Medical Officer, Texas Children's Health Plan||
Cejka Executive Search for Texas Childre's Health Plan